<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082146</url>
  </required_header>
  <id_info>
    <org_study_id>D1050262</org_study_id>
    <nct_id>NCT01082146</nct_id>
  </id_info>
  <brief_title>RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE</brief_title>
  <official_title>A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [Issthiazolyl-3-14C]-Lurasidone Following Postprandial Single Oral Dose Administration in Health Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, non-randomized, absorption, metabolism, and excretion study of
      Lurasidone administered in a suspension at 40 mg to 6 normal healthy male subjects in a
      postprandial state
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of
      [Isothiazolyl-3-14C]-Lurasidone Following Postprandial Single Oral Dose Administration in
      Healthy Male Subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the pharmacokinetics (PK) of a postprandial single dose of 40 mg (150 Ci 5.55 Megabecquerels (MBq)) [Isothiazolyl-3-14C-Lurasidone and its metabolites</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the whole blood and serum concentrations of total radioactivity of [Isothiazolyl-3-14C]-Lurasidone (150 Ci).</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the urinary and fecal recovery of total radioactivity of [Isothiazolyl-3-14C]-Lurasidone (150 Ci).</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety of 40 mg [Isothiazolyl-3-14C]-Lurasidone</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize and identify metabolites of Lurasidone in serum and urine</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine serum concentrations of Lurasidone</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Metabolism</condition>
  <arm_group>
    <arm_group_label>Lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LURASIDONE 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>40 mg suspension, PO, for 7 days</description>
    <arm_group_label>Lurasidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. within a BMI range of 18.0 to 28.0 kg/m2 inclusive;

          2. males will either be sterile or agree to use from Check-in until 45 days following
             Study Completion/Discharge approved methods of contraception

          3. able to comprehend and willing to sign an Informed Consent Form (ICF);

          4. able to void urine on a daily basis and 1 to 2 bowel movements per day.

          5. able to swallow 60 mL of dosing suspension.

        Exclusion Criteria:

          1. history or presence of an abnormal ECG

          2. participation in more than 1 other radiolabeled investigational study drug trial
             within 12 months prior to Check-in.

          3. exposure to significant radiation within 12 months prior to Check-in;

          4. participation in any other investigational study drug trial

          5. use of any prescription medications/products within 14 days prior to Check-in

          6. use of any inhibitors or inducers of CYP3A4 taken within 30 days prior to Check-in,
             including but not limited to drugs listed in Appendix E;

          7. receipt of blood products within 2 months prior to Check-in;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Bohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Global Clinical Research Unit Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Global Clinical Research Unit Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics, lurasidone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

